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Psoriasis is an immune-mediated disease with a genetic basis (1). 
Systemic inflammatory diseases such as psoriasis, systemic lupus 
erythematosus (SLE), and rheumatoid arthritis (RA) are associat-
ed with an increased prevalence of cardiovascular diseases (CVD) 
and other comorbidities (2). In the last decade, screening guide-
lines for cardiovascular (CV) risk factors in patients with psoriasis 
have been published; however, it is uncertain whether they are 
actually applied in clinical practice (3).
 The primary aim of this study was to assess the screening 
practices and awareness among general practitioner (GP) resi-
dents and consultants regarding the most frequent comorbidities 
in patients with psoriasis and to compare this with other known 
systemic inflammatory diseases; namely, RA and SLE.
Methods
We adapted, with permission, the questionnaire used by Parsi 
et al. (3) in 2012, which was distributed to all GP residents and 
consultants that attended two dermatology meetings dedicated to 
GPs in December 2015 and April 2016. The questionnaire identi-
fied the various comorbidity screening practices in patients with 
psoriasis and other systemic inflammatory disease, including SLE 
and RA.
Statistical analysis
In Portugal GP residents must perform a 4-year residency in order 
to become consultants. For the results analysis, the participants 
were divided into three groups: GP residents in the first 2 years 
of residency, GP residents in the last 2 years of residency, and GP 
consultants.
All statistical analyses were performed using SPSS version 20.0 
(IBM, Armonk, NY). Categorical variables were compared using 
McNemar’s test, Fisher’s exact test, or a chi-square test. We con-
sidered the significance level to be p < 0.05.
Results
Overall, 372 questionnaires were collected; 283 (76.1%) participants 
were women and 299 (80.4 %) were under 30 years old (Table 1).
GP trainees in the first 2 years of residency were the largest 
group, with 271 (72.8%) residents; GP residents in the last 2 years 
of residency group numbered 79 (21.2%) participants; and the 
group of GP consultants numbered 16 (4.3%; Table 1).
Psoriasis was perceived as a systemic disease by the majority 
of physicians (328/372; 88.2%). A significantly greater number rec-
ognized SLE (366/372; 98.4%, p < 0.001) and RA (359/372; 96.5%, p 
< 0.001) as systemic diseases (Table 2).
An increased mortality risk in psoriasis patients was recog-
nized by 149/372 (40.1%) physicians. A significantly greater num-
ber recognized SLE (339/372; 91.1%, p < 0.001) and RA (288/372, 
77.4%, p < 0.001) as having increased mortality (Table 2).
Physicians were almost twice as likely to be aware of the in-
creased CV risk in patients with RA than in those with psoriasis 
(72.3% vs. 36.3%, p < 0.001) and 2.5 times more likely in SLE pa-
tients than in those with psoriasis (92.7% vs. 36.3%, p < 0.001) 
(Table 2).
There were no statistically significant differences between the 
three groups studied concerning the recognition of psoriasis as a 
systemic disease or as having an increased CV risk (p > 0.05; Table 
3). A higher number of GP residents in the final stage of residency 
identified psoriasis as having increased mortality compared to GP 
residents in the early stage of residency, and this difference was 
statistically significant (50.6% vs. 37.3%, p = 0.019). However, this 
difference was not statistically significant when the GP residents 
were compared with GP consultants.
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The number of patients seen per month, their sex, and their 
age did not affect the recognition of psoriasis as a systemic dis-
ease or as having an increased mortality and CV risk (p > 0.05).
Concerning the screening practices of CV risk factors in patients 
with psoriasis, 180 (48.4%) of participants usually screen for hy-
pertension (HT), 134 (36.0%) for obesity, 138 (37.1%) for diabetes 
mellitus (DM), and 129 (34.7%) for dyslipidemia. Significantly 
more physicians usually screen for CV risk factors in patients with 
SLE than in those with psoriasis; namely HT (73.9% vs. 48.4%, 
p < 0.001), obesity (41.9% vs. 36%, p < 0.001), DM (53.2% vs. 37.1%, 
p < 0.001), and dyslipidemia (53.2% vs. 34.7%, p < 0.001; Table 
2). Similarly, a significantly higher number of physicians usually 
screen these risk factors in patients with RA than in those with 
psoriasis, particularly HT (69.6% vs. 48.4%, p < 0.001), obesity 
(48.1% vs. 36%, p < 0.001), DM (51.6% vs. 37.1%, p < 0.001), and 
dyslipidemia (47.9% vs. 34.7%, p < 0.001), Table 2. Hypertension 
was the most frequently screened risk factor in all diseases.
There were no statistically significant differences regarding the 
screening of arthritis in patients with psoriasis and those with SLE 
(62.6% vs. 68.3%, p > 0.05) or RA (62.6% vs. 67.2%, p > 0.05) (Table 
2).
Only 167 (44.9%) physicians stated that they systematically 
screen for depression in psoriasis patients. Significantly more 
usually screen for depression in patients with SLE (55.9% vs. 
44.9%, p < 0.001) and those with RA (54.8% vs. 44.9%, p < 0.001) 
than in those with psoriasis (Table 2).
There were no statistically significant differences between GP 
residents in the initial and final stage of residency, or between GP 
residents and consultants with respect to CV risk factor screening 
practices in psoriasis patients (Table 3).
Discussion
In recent decades, there has been a growing awareness of an as-
Table 1 | Characteristics of the study participants (n = 372).
Total participants
n (%)
Residents, 1st and 2nd years
n (%)




Year of GP residency
1st 187 (50.3) 187 (50.3)
2nd 84 (22.6) 84 (22.6)
3rd 58 (15.6) 58 (15.6)
4th 21 (5.6) 21 (5.6)
GP consultants 16 (4.3) 16 (4.3)
Not stated 6 (1.6)
Sex
Female 283 (76.1) 207 (76.4) 61 (77.2) 12 (75.0)
Male 86 (23.1) 62 (22.9) 18 (22.8) 3 (18.8)
Not stated 3 (0.8) 2 (0.7) 0 1 (6.2)
Age (years)
< 30 299 (80.4) 243 (89.7) 52 (65.8) 0
30–35 51 (13.7) 21 (7.7) 26 (32.9) 2 (12.6)
35–40 5 (1.3) 3 (1.1) 1 (1.3) 1 (6.2)
> 40 13 (3.5) 1 (0.4) 0 12 (75.0)
Not stated 4 (1.1) 3 (1.1) 0 1 (6.2)
GP = general practitioners.
Table 2 | Analysis of screening practices by disease group.
Psoriasis n (%) SLE n (%) RA n (%) pa psoriasis vs. SLE pa psoriasis vs. RA
Systemic disease? 328 (88.2) 366 (98.4) 359 (96.5) < 0.001 < 0.001
Increased mortality? 149 (40.1) 339 (91.1) 288 (77.4) < 0.001 < 0.001
Increased CV risk? 135 (36.3) 345 (92.7) 269 (72.3) < 0.001 < 0.001
Screening practices
Hypertension 180 (48.4) 275 (73.9) 259 (69.6) < 0.001 < 0.001
Diabetes mellitus 138 (37.1) 198 (53.2) 192 (51.6) < 0.001 < 0.001
Obesity 134 (36.0) 156 (41.9) 179 (48.1) 0.040 < 0.001
Dyslipidemia 129 (34.7) 198 (53.2) 178 (47.9) < 0.001 < 0.001
Depression 167 (44.9) 208 (55.9) 204 (54.8) < 0.001 < 0.001
Arthritis 233 (62.6) 254 (68.3) 250 (67.2) 0.088 0.160
SLE = systemic lupus erythematosus, RA = rheumatoid arthritis, CV = cardiovascular.
a Categorical variables were compared using McNemar’s test, Fisher’s exact test, or a chi-square test.
Table 3 | Analysis of screening practices by study group.
Psoriasis Residents, 1
st and 2nd years 
n (%)




pa residents vs. 
residents
pa residents vs. 
consultants
Systemic disease? 237 (87.5) 72 (91.1) 15 (93.8) 0.370 0.502
Increased mortality? 101 (37.3) 40 (50.6) 5 (31.3) 0.019 0.438
Increased CV risk? 95 (35.1) 30 (38.0) 7 (43.8) 0.469 0.554
Screening practices
Hypertension 131 (48.3) 41 (51.9) 8 (50.0) 0.714 0.584
Diabetes mellitus 96 (35.4) 36 (45.6) 6 (37.5) 0.159 0.250
Obesity 95 (35.1) 32 (40.5) 7 (43.8) 0.507 0.299
Dyslipidemia 96 (35.4) 27 (34.2) 6 (37.5) 0.615 0.432
Depression 122 (45.0) 37 (46.8) 8 (50.0) 0.291 0.769
Arthritis 173 (63.8) 50 (63.3) 10 (62.5) 0.199 0.808
SLE = systemic lupus erythematosus; RA = rheumatoid arthritis; CV = cardiovascular.
a Categorical variables were compared using McNemar’s test, Fisher’s exact test, or a chi-square test.
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sociation between psoriasis and a variety of comorbidities, which 
include psoriatic arthritis, inflammatory bowel disease, depres-
sion, metabolic syndrome, nonalcoholic fatty liver disease, lym-
phoma, and erectile dysfunction (4–8). In fact, patients with pso-
riasis have an increased risk of CVD and CV mortality. Depression 
itself is also associated with an increased risk of CVD (5, 6).
The exact mechanism of the psoriasis-CVD association re-
mains unclear, but it may involve humoral and cellular inflam-
matory mediators (7). Atherosclerosis exhibits many similarities 
to psoriasis and other chronic inflammatory diseases such as SLE 
and RA regarding the immune process, the humoral mediators 
profile, and the immune cells involved in the pathogenesis (4, 7). 
Taken together, these studies suggest that psoriasis itself may be 
an independent risk factor for developing CVD (5).
Recently a consensus group proposed an integrated approach 
to comorbidities in patients with psoriasis, including CV risk fac-
tors (4). They recommended that patients with mild psoriasis 
should be screened annually and those with severe psoriasis eve-
ry 6 months. CV screening include recording weight, height, body 
mass index, waist circumference, blood pressure, total, LDL, and 
HDL cholesterol, triglycerides, fasting plasma glucose, and glyco-
sylated hemoglobin evaluation. In addition, patients should be 
asked about tobacco and alcohol consumption and evaluated for 
signs and symptoms of arthritis, nonalcoholic fatty liver disease, 
inflammatory bowel disease, lymphoma, and depression (4).
The majority of GP trainees and specialists that participated in 
this study do not usually screen for HT, DM, dyslipidemia, obe-
sity, and depression in psoriasis patients and are not aware of an 
increased CV risk and mortality in patients with psoriasis. Moreo-
ver, they assign greater importance regarding CV risk factors and 
increased mortality to other inflammatory diseases; namely, RA 
and SLE.
Across residency, the screening practices did not change sig-
nificantly, pointing to the fact that this knowledge is not acquired 
during the residency program. Furthermore, although most physi-
cians usually screen for arthritis on psoriasis patients, more than 
one-third still do not.
This study found holes in the Portuguese GP residency pro-
gram concerning psoriasis. Efforts are needed to improve GPs’ 
awareness concerning comorbidities associated with psoriasis.
Limitations of the study include the potential for reporting 
bias, which is inherent to questionnaire-based methodology. An-
other limitation is related to the great imbalance between the dif-
ferent groups, which conditions the analysis, especially due to the 
small number of GP consultants.
Conclusion
Psoriasis is a systemic inflammatory disease. Because GPs are in a 
sentinel-like position to detect and respond to psoriasis patients’ 
comorbidities, it is essential to alert GPs about the comorbidities 
in psoriasis patients and the relevance of CV risk factor screening 
in this population.
Acknowledgements
The authors thank Kory Parsi, Elizabeth Brezinski, Tzu-Chun Lin, 
Chin-Shang Li, and April Armstrong for having given us permis-
sion to use their questionnaire, which formed the basis for this 
study.
References
1. Lee MK, Kim HS, Cho EB, Park EJ, Kim KH, Kim KJ. A study of awareness and 
screening behavior of cardiovascular risk factors in patients with psoriasis and 
dermatologists. Ann Dermatol. 2015;27:59–65.
2. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoria-
sis and psoriatic arthritis: immunological aspects and therapeutic guidelines. 
Clin Exp Rheumatol. 2006;24:S72–S78.
3. Parsi KK, Brezinski EA, Lin TC, Li CS, Armstrong AW. Are patients with psoriasis 
being screened for cardiovascular risk factors? A study of screening practices 
and awareness among primary care physicians and cardiologists. J Am Acad 
Dermatol. 2012;67:357–62.
4. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, 
et al. Integrated approach to comorbidity in patients with psoriasis. Working 
Group on Psoriasis-Associated Comorbidities. Actas Dermosifiliogr. 2012;103 
Suppl 1:1–64.
5. Oliveira MF, Rocha BO, Duarte GV. Psoriasis: classical and emerging comorbidi-
ties. An Bras Dermatol. 2015;90:9–20.
6. Egeberg A. Psoriasis and comorbidities. Epidemiological studies. Dan Med J. 
2016;63:1–11.
7. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et 
al. Clinical practice guideline for an integrated approach to comorbidity in pa-
tients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27:1387–404.
8. Madanagobalane S, Anandan S. Prevalence of metabolic syndrome in south In-
dian patients with psoriasis vulgaris and the relation between disease severity 
and metabolic syndrome: a hospital-based case-control study. Indian J Derma-
tol. 2012;57:353–7.
